Last reviewed · How we verify
Galderma Brasil Ltda. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Adapalene-BPO Gel | Adapalene-BPO Gel | marketed | Retinoid + peroxide combination | Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide) | Dermatology |
Therapeutic area mix
- Dermatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Derm Research, PLLC · 1 shared drug class
- GWT-TUD GmbH · 1 shared drug class
- Galderma R&D · 1 shared drug class
- Padagis LLC · 1 shared drug class
- Stiefel, a GSK Company · 1 shared drug class
- Wake Forest University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Galderma Brasil Ltda.:
- Galderma Brasil Ltda. pipeline updates — RSS
- Galderma Brasil Ltda. pipeline updates — Atom
- Galderma Brasil Ltda. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Galderma Brasil Ltda. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/galderma-brasil-ltda. Accessed 2026-05-17.